首页> 外文期刊>Nature reviews Cancer >MITOCHONDRIAL TUMOUR SUPPRESSORS: A GENETIC AND BIOCHEMICAL UPDATE
【24h】

MITOCHONDRIAL TUMOUR SUPPRESSORS: A GENETIC AND BIOCHEMICAL UPDATE

机译:线粒体肿瘤抑制物:遗传和生物化学的更新。

获取原文
获取原文并翻译 | 示例
       

摘要

Abstract | Since the discovery 5 years ago that the D-subunit of succinate dehydrogenase (SDHD) can behave as a classic tumour suppressor, other nuclear-encoded mitochondrial proteins (SDHB, SDHC and fumarate hydratase) have been implicated in tumour susceptibility. Mutations in these proteins are principally involved in familial predisposition to benign tumours, but the spectrum of inherited lesions is increasingly recognized to include malignant tumours, such as malignant phaeochromocytomas and renal cell carcinomas. Here we review recent advances in the field of mitochondrial tumour suppressors, the biochemical pathway that links mitochondrial dysfunction with tumorigenesis, and potential therapeutic approaches to these malignancies.
机译:摘要|自5年前发现琥珀酸脱氢酶(SDHD)的D亚基可以起经典的抑癌作用以来,其他核编码的线粒体蛋白(SDHB,SDHC和富马酸水合酶)都与肿瘤易感性有关。这些蛋白质的突变主要与家族性易患良性肿瘤有关,但是越来越多的遗传病灶包括恶性肿瘤,例如恶性嗜铬细胞瘤和肾细胞癌。在这里,我们回顾了线粒体抑癌剂领域中的最新进展,将线粒体功能障碍与肿瘤发生联系起来的生化途径,以及针对这些恶性肿瘤的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号